Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Patients With Type 2 Diabetes With an Interleukin-1 Antagonist

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age \>20~* Diabetes mellitus Type 2 (American Diabetes Association criteria) of at least 3 months duration~* HbA1c \>7.5%~* Body-mass index (BMI) \> 27~Exclusion Criteria:~* Positive GAD 65 or IA-2 antibodies at inclusion.~* HbA1c \>12%, polyuria and thirst (exclusion of severely decompensated patients)~* C-peptide \< 400pmol/l (basal )~* Established anti-inflammatory therapy (includiung cortisone, NSAID, Cox-2-inhibitor). Low dose aspirin (£ 100mg) will be tolerated.~* CRP \>30 mg/dl, fever, current treatment with antibiotics, or chronic granulomatous infections (e.g. tuberculosis) in the history or on a screening chest X-ray.~* Neutropenia or anemia (leucocyte count \< 2.0x109 /l, hemoglobin \<11g/dl for ma les or \<10g/dl for females)~* Pregnancy or breast-feeding. When appropriate (fertile women),anticonception for at last 3 month prior inclusion will be required.~* Severe liver or renal disease ( AST or ALT\>3 times the upper limit of normal laboratory range, serum creatinine \>130mM)~* Ongoing malignant neoplasm~* Use of any investigational drug within 30 days of enrollment into the study or within 5 half-lives of the investigational drug (whichever is longer)~* Immunosuppressive treatment or immunodeficient diseases.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).